Does MaineCare Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules

No. As of November 2026, MaineCare, Maine’s Medicaid program, does not cover Wegovy, Zepbound or any other drug for weight loss alone; its drug list says weight-loss drugs “are not covered.”^[1] It does pay for Wegovy with prior authorization to cut heart risk or treat the liver disease MASH in adults with a BMI over 27, and for Zepbound in adults with sleep apnea once CPAP has failed or could not be tolerated.^[1][2]

Will MaineCare pay for a GLP-1 to lose weight?

It will not. The weight-loss row of the drug list names phentermine and Xenical as no longer covered and says weight-loss drugs are excluded under federal Medicaid rules and MaineCare policy.^[1] The Wegovy form repeats the point with a yes-or-no question asking whether the drug is for weight loss only.^[2] Under federal law, states may leave these drugs out, and Maine does.^[6] Our explainer on how Medicaid splits diabetes and weight-loss GLP-1s covers the federal side.

MaineCare also stopped covering orlistat and phentermine, so there is no older weight-loss drug to fall back on through the program.^[1]

Has Maine tried to add weight-loss coverage?

Yes, and it failed. LD 480, a 2025 bill to make MaineCare pay for GLP-1s approved for obesity, was voted out of committee as ought not to pass on March 20, 2025.^[4] At the hearing, the MaineCare medical director testified that after rebates the benefit would cost more than $42 million in state fiscal 2026 and $53 million in 2027, with $14.5 million and $18.4 million of that from the state’s general fund.^[5] The same testimony said MaineCare already covers GLP-1s for diabetes and would follow federal law in covering newly approved uses such as sleep apnea, which is the pattern the current drug list follows.^[5][1] We found no later bill that changed the rule as of November 2026.

When does MaineCare cover Wegovy?

For two uses beyond weight. On the October 2026 list, Wegovy sits in a class called cardiometabolic health agents, where the injection and the tablet are preferred drugs that still need clinical prior authorization.^[1] The prescriber uses Form #23976, and a first approval lasts three months.^[2]

Three details trip up requests. The BMI must be over 27, so a reading of exactly 27 does not qualify.^[1] The MASH route is for the injection only, which matches the label: Wegovy tablets are not approved for MASH.^[2][9] And the heart route asks for chart notes, not just a diagnosis code.^[2] The form asks whether the patient has diabetes and which drugs they have tried, but neither the form nor the drug list bars people with diabetes from the heart or liver routes.^[1][2] Our page on GLP-1s for fatty liver disease and MASH explains the trial behind the liver approval.

Does MaineCare cover Zepbound for sleep apnea?

Yes, under criteria stricter than the drug’s label. Zepbound is listed under its own sleep apnea heading and is requested on the general form, #20420.^[1] Every one of these must be true:^[1]

• The patient is 18 or older, with a BMI from 30 up.
• A sleep study in the last three years shows moderate to severe sleep apnea, scored at 15 or more on the apnea-hypopnea index (AHI).
• CPAP has not worked, meaning the AHI stayed above 5 on the treatment part of the study, or the patient could not tolerate CPAP for at least 90 days.
• At least three months of diet and activity changes failed to bring weight down.
• There is no diabetes of either type on record.

The CPAP and lifestyle steps go beyond the label, which approves Zepbound for moderate to severe sleep apnea in adults with obesity without asking for a CPAP failure first.^[8] A sleep study older than three years means a new one before filing. People with diabetes are steered to the diabetes drugs instead.^[1] Our guide to tirzepatide for sleep apnea covers the trials behind the approval.

Does MaineCare cover Ozempic and Mounjaro for diabetes?

Ozempic, yes, with prior authorization; Mounjaro does not appear on the list. The preferred diabetes GLP-1s on the October 2026 drug list are Rybelsus, Trulicity and Victoza, with no prior authorization marker.^[1] Ozempic is non-preferred, sixth in the step order, and the list says preferred drugs must be tried and fail before a non-preferred one is approved, unless the form gives an accepted clinical reason.^[1] We searched the list for Mounjaro and tirzepatide and found only the Zepbound sleep apnea row.^[1] A prescriber who wants Mounjaro should call the prior authorization help desk before writing it.

How do you file, and who do you call?

The form must be legible and complete or it is returned, and it takes one drug per form.^[2] The help desk numbers come from the state’s pharmacy site.^[3]

How do you appeal a MaineCare denial?

Check the reason first. A denial for a sleep study more than three years old, a missing CPAP record or a BMI of exactly 27 is usually fixed by refiling with the right record.^[1] A denial because the drug is for weight loss alone has no route to win, because MaineCare excludes that use.^[1]

For a hearing, federal rules let a state set the deadline but cap it at 90 days from the date the notice is mailed.^[7] Use the date on your notice, and call the pharmacy hearings coordinator if it is unclear.^[3] Our walkthrough of building a prior authorization or appeal file covers what to send, and the Maine state page keeps the basics in one place.

What can you do if MaineCare will not pay?

Cash is the main option, and Lilly’s savings card excludes anyone on Medicaid.^[10] In the figures we track, Novo Nordisk’s self-pay price for most Wegovy pen doses is $349 a month, and Lilly’s self-pay Zepbound costs $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time.^[10][11] Read each program’s terms on government coverage first. Our list of the cheapest ways to buy a GLP-1 without insurance compares them.